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ABBREVIATION LIST 
Ao  aorta 
BAL  broncho-alveolar lavage 
CI  confidence interval 
CPI  composite physiologic index 
CT  computed tomography 
DA  decreased attenuation 
DLco  diffusing capacity for carbon monoxide 
FEV1  forced expiratory volume in one second 
FVC  forced vital capacity 
GGO  ground glass opacity 
HR  hazard ratio 
ILD  interstitial lung disease 
IPF  idiopathic pulmonary fibrosis 
Kco  carbon monoxide transfer coefficient 
MDT  multi-disciplinary team 
PA  pulmonary artery 
PFT  pulmonary function test 
PVV  pulmonary vessel volume 
RVSP  right ventricular systolic pressure 
TLC  total lung capacity 
TxBx  traction bronchiectasis 
uILD unclassifiable interstitial lung disease 
UIP  usual interstitial pneumonia  
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ABSTRACT 
Background: Unclassifiable-interstitial lung disease (uILD) represents a 
heterogeneous collection of pathologies encompassing those fibrosing lung diseases 
which do not fulfill current diagnostic criteria. We evaluated baseline and 
longitudinal functional and CT (visual and quantitative computer [CALIPER] analysis) 
variables to identify outcome predictors in uILD. 
 
Methods: Consecutive patients with uILD on multidisciplinary review (n=95) had 
baseline functional (FVC, DLco, CPI [composite physiologic index]) and CT features 
(visual evaluation: CT pattern, fibrosis extent, honeycombing presence, traction 
bronchiectasis severity, pulmonary artery (PA) diameter; CALIPER evaluation: fibrosis 
extent, pulmonary vessel volume (PVV)) examined in univariate and multivariate Cox 
regression models. Change in functional and CT variables were examined in a patient 
subset (n=37), to identify indicators of outcome. 
 
Results: On univariate analysis, CPI was the most powerful functional predictor of 
mortality (p<0.0001).  Visual traction bronchiectasis (p<0.0001), PA diameter 
(p<0.0001) and honeycombing presence (p=0.0001) and CALIPER PVV (p=0.0003) 
were the strongest CT outcome predictors. 
 
On multivariate analysis of baseline indices, traction bronchiectasis (p=0.003), PA 
diameter (p=0.003) and CPI (p=0.0001) independently predicted mortality. 
Colinearity with functional indices precluded the evaluation of CALIPER PVV in 
multivariate models. 
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On evaluation of longitudinal variables, increasing CALIPER fibrosis extent was the 
strongest outcome predictor, and remained so following adjustment for baseline 
disease severity, and when FVC declines were marginal. 
 
Conclusions: In uILD patients, CPI, traction bronchiectasis severity and PA diameter 
independently predicted outcome at baseline. Increasing fibrosis extent measured 
by CALIPER was the most powerful index of outcome regardless of baseline disease 
severity and strongly predicted outcome in patients with marginal FVC declines. 
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INTRODUCTION 
Multi-disciplinary teams (MDT) meetings are widely viewed as the preferred means 
of characterizing interstitial lung diseases1, 2 and has improved agreement of the 
diagnosis of ILD between centres3. However, it is increasingly recognized that 
following MDT discussion, 10-25% of cases of interstitial lung disease cannot be 
classified and are labeled unclassifiable-ILD (uILD)4-10.  
 
Concerns with regard to the increased mortality associated with surgical lung biopsy 
has reduced the number of such procedures being performed, with the result that 
many patients are today evaluated using radiological and clinical data only in an 
MDT discussion4. Nevertheless, patients with uILD are ideally monitored in an MDT 
setting in case emerging clinical data allow a diagnostic label to be applied6.  
 
Our study aimed to characterize those baseline and longitudinal variables that best 
predict mortality in patients with uILD using a combination of clinical variables, 
functional indices and visual and computer-identified CT features.  
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METHODS 
Clinical Data 
The study population consisted of all consecutive new patients presenting over a 
four and a half year period (January 2007 to July 2011) who on re-examination in a 
multi-disciplinary team (MDT) setting were assigned a diagnosis of uILD. A diagnosis 
of uILD was reached if, following MDT discussion, a single diagnosis (in accordance 
with standard criteria where available2, 11-13) could not be reached with over 50% 
diagnostic certainty. Patients who had undergone a non-contrast, supine, volumetric 
thin section CT scans were selected and exclusions are shown in the flowchart in the 
Supplementary Appendix (Figure 1).  
 
Standardized CT scanning protocols, CALIPER protocols and echocardiographic and 
pulmonary function test (PFT) protocols were utilized 14, 15. Echocardiographic and 
PFT data was considered if performed within 3 months of the CT scan. Functional 
indices analysed in the current study included: forced expiratory volume in one 
second (FEV1), forced vital capacity (FVC), diffusing capacity for carbon monoxide 
(DLco), carbon monoxide transfer coefficient (Kco), total lung capacity (TLC), and the 
composite physiological index (CPI). The composite physiologic index is a score that 
considers varied weightings of FEV1, FVC and DLco (CPI = 91 - (0.65 x % predicted 
DLco) - (0.53 x % predicted FVC) + (0.34 x % predicted FEV1)) and was derived to 
account for the morphologic extent of pulmonary fibrosis on CT, correcting for the 
confounding effects of emphysema16. 
 
 8 
Approval for this study of clinically indicated CT and pulmonary function data was 
obtained from the Institutional Ethics Committee of the ___________ and 
_________ and informed patient consent was not required. 
 
 
Visual and CALIPER CT analysis 
In accordance with a landmark study of uILD4, classification of CT patterns into 
definite, possible and inconsistent UIP patterns according to accepted diagnostic 
criteria for idiopathic pulmonary fibrosis (IPF)2 was performed by JJ (5 years thoracic 
imaging experience). Visual CT scoring was performed independently by two of four 
radiologists (AN and SLW or ALB and RE) with 5 to 9 years thoracic imaging 
experience, blinded to all clinical information. The same scorer pairs evaluated the 
same patient’s serial CT (performed 6-30 months after the initial CT) when available, 
and the scorers were blinded to the time points of the serial CTs. Consenus 
formulation for visual CT scores is outlined in the Supplementary Appendix. 
 
CT patterns scored visually as a percentage of a lobe included: ground glass opacity, 
reticular pattern, honeycombing and emphysema. The lobar scores for a single 
parenchymal pattern were summed and divided by 6 (the left upper lobe and lingula 
were considered as separate lobes) to generate a total lung percentage for each 
parenchymal pattern Traction bronchiectasis severity17 was evaluated using a 
categorical four-point lobar scale (none=0, mild=1, moderate=2, severe=3) that 
reflected both the degree of airway dilatation within areas of fibrosis and the 
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number of lobar segments containing airways dilated secondary to fibrosis. Lobar 
scores were summed for six lobes resulting in a 19-point scale.  
 
Indices reflecting pulmonary hypertension included the main pulmonary artery 
diameter and the main pulmonary artery:ascending aorta ratio. Both were assessed 
by one scorer using electronic caliper diameter measurements of the ascending 
aorta and pulmonary artery diameters at the level of the pulmonary artery 
bifurcation18. Details regarding scoring methodology and consensus formulation 
have been previously described.14  
 
CALIPER represents a computer tool developed by the Biomedical Imaging Resource 
at the Mayo Clinic Rochester. CALIPER evaluates structural, textural and histogram 
characteristics of 15x15x15 voxel volume units across contiguous volumetric CT 
datasets, and classifies each voxel into one of eight patterns: normal lung, ground 
glass opacity, reticular pattern, honeycombing, three grades of low parenchymal 
attenuation and the pulmonary vessel volume (PVV). The PVV represents the total 
volume of pulmonary arteries and veins excluding vessels at the lung hilum19. 
Regarding the three grades of low parenchymal attenuation, Grade 2 and 3 low 
attenuation areas correspond to emphysema, whilst grade 1 low attenuation 
predominantly corresponds to normal lung14. The total lung volume of each of the 
eight CALIPER parenchymal patterns was divided by the total lung volume calculated 
by CALIPER to derive a total lung percentage for each parenchymal pattern. 
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For both visual and CALIPER scores, total fibrosis extent represented the sum of 
reticular pattern and honeycombing, whilst total ILD extent additionally summed 
ground glass opacities. For serial CT analyses, absolute change in CT patterns 
(Timepoint 2 minus Timepoint 1) expressed as a percentage of the lungs was 
calculated. 
 
Calculation of change in CT and pulmonary function variables 
Change in all CT variables and change in the composite physiologic index (CPI) were 
expressed as absolute change per year. Change in FVC and DLco was expressed as 
absolute and relative change per year. Kco and TLC change were only expressed as 
relative change per year. 
 
Statistical analysis 
Data are given as medians or means with standard deviations depending on 
distributions, or numbers of patients with percentages where appropriate. 
Interobserver variation for visual scores was assessed using the single determination 
standard deviation for continuous variables and the kappa statistic for categorical 
variables. Differences between groups were evaluated using a Chi-squared test for 
categorical variables or the T-test for normally distributed continuous variables and 
the Mann Whitney-U test for non-normally distributed variables. Statistical 
significance was evaluated at a value of p<0.05. Univariate and multivariate linear 
and logistic regression analyses were used to investigate relationships between 
variables. Univariate and multivariate Cox regression analyses were used to 
investigate variables predictive of mortality. Kaplan Meier survival curves were 
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compared using the Log rank test. Assumptions of linearity and proportional hazards 
were tested by visual inspection of Martingale residuals and scaled Schoenfeld 
residuals and were satisfied. Statistical analyses were performed with STATA (version 
12, StatCorp, College Station, TX, USA). 
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RESULTS 
Population demographics 
107/1072 (10%) consecutive patients presenting to the ____________ ILD unit when 
re-examined were regarded as uILD. 12 patients without departmental imaging were 
excluded and 95 patients were examined in the study (Supplementary Figure 1). 
Demographic data, mean visual CT scores, CALIPER scores, echocardiographic and 
pulmonary function test data are provided in Table 1. Change in CT and pulmonary 
function variables in 37 patients with serial imaging (median follow up time=1.27 
years) and functional data is provided in Supplementary Table 1. Interobserver 
variation values for baseline and longitudinal visual scores are shown in 
Supplementary Tables 2a+b respectively.  
 
The median patient age was 65 years and most patients were female and never 
smokers. At the end of the study follow up period, 45/95 (47%) patients were alive. 
One patient received a lung transplant and was censored at the time of 
transplantation. Only 21/95 [22%] patients underwent a surgical lung biopsy, with 
the majority demonstrating overlapping disease patterns on histology.  
 
6/95 (6%) patients demonstrated a definite UIP pattern on CT, 25/95 (26%) patients 
had a possible UIP pattern, whilst 64/95 (67%) CTs were inconsistent with a UIP 
pattern. Criteria by which a CT pattern inconsistent with UIP was assigned are shown 
in Supplementary Table 3. For the 6 patients with a definite UIP pattern on CT, in 
three cases there was discrepancy between CT findings and histopathology, and in 
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three cases there was discrepancy between CT findings and clinical features 
(Supplementary Table 4). 
 
Baseline results 
On univariate analysis of CALIPER variables, the PVV (p=0.0003; C-Index=0.69) and 
CALIPER fibrosis extent (p=0.001) were the strongest predictors of mortality. 
Univariate analysis of visual CT variables identified traction bronchiectasis 
(p<0.0001) the PA diameter (p<0.0001) and the presence of honeycombing 
(n=52)[p=0.0001] as the strongest predictors of mortality. All PFTs except Kco were 
strongly predictive of outcome.  
 
PVV was strongly associated with CALIPER ILD and fibrosis extent (R2=0.73 and 0.47 
respectively). PVV also showed strong linkages with other measures of baseline 
interstitial disease severity (DLco R2=0.50; CPI R2=0.61), and therefore PVV was not 
examined in multivariate models alongside functional indices. 
 
In patients undergoing transthoracic echocardiography (n=82/95, 86%), no 
difference in baseline variables (age, gender, DLco, CPI [composite physiologic 
index], CALIPER ILD extent, visual ILD extent) was present when compared to 
patients that did not undergo transthoracic echocardiography (n=13/95; 14%). In the 
53/95 patients with a measured RVSP, only weak correlations were identified with 
visually-scored PA diameter (R2=0.28, p<0.0001), CALIPER PVV (R2=0.01, p=0.52), 
DLco (R2=0.08, p=0.05), and Kco (R2=0.08, p=0.04). 
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Multivariate mortality analyses 
On multivariate Cox regression analysis of CALIPER variables alone, PVV remained 
the strongest independent predictor of mortality, and improved in strength after 
correcting for patient age and gender (HR=1.23, CI 1.11-1.37, p<0.0001).  
 
When visually derived CT indices were evaluated in a multivariate model, traction 
bronchiectasis (HR=1.17, CI 1.05-1.31, p=0.005) the presence of honeycombing 
(HR=2.18, CI 1.02-4.64, p=0.04) and PA diameter (HR=1.10, CI 1.05-1.16, p<0.0001) 
were independently predictive of mortality. When PFTs were examined, CPI was 
strongest single predictor of mortality.  
 
When combined visual CT indices and the CPI were analysed, the resulting three 
independent predictors of mortality were: CPI (HR=1.06, CI 1.03-1.09, p=0.0002), 
traction bronchiectasis (HR=1.16, CI 1.05-1.28, p=0.003) and PA diameter (HR=1.08, 
CI 1.03-1.14, p=0.003). When DLco was substituted for CPI as a severity variable, 
the results were essentially unchanged: DLco (HR=0.95, CI 0.93-0.98, p=0.0005), 
traction bronchiectasis (HR=1.18, CI 1.07-1.30, p=0.001) and PA diameter (HR=1.08, 
CI 1.03-1.14, p=0.003). The three CT patterns (definite, possible and inconsistent 
with UIP) did not have any independent prognostic value. In all multivariate models, 
results were maintained when adjusting for patient age and gender. Results were 
also maintained in a separate subanalysis excluding five patients that demonstrated 
no traction bronchiectasis on CT. 
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Serial Analyses 
When measures of longitudinal change were examined using univariate analyses in a 
subset of 37 patients with follow up data, the strongest predictors of outcome were 
relative FVC change, change in PVV and change in fibrosis extent measured visually 
and by CALIPER (Table 3). Following adjustment for baseline disease severity using 
CPI, change in CALIPER fibrosis extent (p=0.001, HR=1.16, CI 1.06-1.28) better 
predicted outcome than either change in visual fibrosis extent (p=0.01, HR=1.08, CI 
1.02-1.14) or relative FVC change (p=0.003, HR=0.94, CI 0.90-0.98). The results were 
maintained when DLco was used to adjust for baseline disease severity. When 
examined alongside variables shown previously to predict outcome in uILD, CALIPER 
fibrosis change was a stronger predictor of outcome than baseline visual fibrosis 
extent and severity thresholds of DLco<35 % predicted and visual fibrosis extent 
>20%.  
 
When group differences in baseline measures between patients with and without 
follow up imaging were examined to identify potential selection biases, the only 
significant difference between groups was the PA diameter (p=0.01)[Supplementary 
Table 5]. Kaplan-Meier survival curves did not significantly differ between groups 
with and without follow up imaging (Log rank test=0.17). Results were again 
maintained when two patients without traction bronchiectasis were excluded.  
 
Predictors of disease progression 
In 29/34 patients with <10% predicted relative FVC decline, the variables strongly 
predictive of outcome on univariate analysis remained unchanged (Table 4). After 
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adjustment for baseline disease severity using DLco, change in CALIPER fibrosis 
extent (p=0.0004, HR=1.19, CI 1.08-1.32) better predicted outcome than change in 
visual fibrosis extent (p=0.01, HR=1.07, CI 1.02-1.13), PVV change (p=0.02, HR=1.98, 
CI 1.09-3.58), relative FVC change (p=0.004, HR=0.94, CI 0.90-0.98) and relative DLco 
change (p=0.03, HR=0.96, CI 0.92-1.00). PVV change was independently predictive of 
outcome when examined alongside visual and CALIPER fibrosis extent change in 
separate models.  
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DISCUSSION 
Our study has identified several new findings in patients with uILD. Firstly, at 
baseline, the CPI was the pulmonary function measure that best predicted mortality. 
Secondly, the strongest CT predictors of outcome were the severity of traction 
bronchiectasis and the pulmonary artery diameter. However when adjusting for 
baseline disease severity, change in CALIPER fibrosis extent was a stronger predictor 
of outcome than baseline or other longitudinal variables. Importantly, in patients 
with only marginal FVC change, change in CALIPER fibrosis extent was the stronger 
predictor of outcome. 
 
Our findings regarding the prevalence of uILD in our tertiary centre, and the 
proportion of patients undergoing an surgical lung biopsy are both in line with 
previous reports4-6, 20, 21. UILD is often associated with the absence of histological 
data4, with only 22% of patients in our cohort undergoing a diagnostic surgical lung 
biopsy. When histopathological assessment was possible, an overlap of patterns was 
seen in most cases, which when combined with a non-specific CT pattern and 
indeterminate clinical features led to no single diagnosis being favoured. 
 
Amongst baseline CALIPER variables, PVV was the strongest determinant of 
mortality, reproducing findings identified in other fibrosing lung diseases15, 22. PVV 
was also found to be a more malignant prognostic determinant in patients with 
increased fibrosis on CT. Regarding the visual CT variables that were independently 
predictive of mortality, traction bronchiectasis severity23-26 and the pulmonary artery 
diameter27, 28 have both been previously shown to strongly predict outcome across 
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various fibrosing lung diseases, but were not examined in previous studies 
investigating uILD4, 29.  
 
In a previous study detailing a population of patients with uILD, Ryerson et al4 
classified patients according to current consensus IPF-CT diagnostic guidelines30. In 
our study, the weak link between a definite UIP pattern and outcome (p=0.04) was 
similar to the weak links for combined definite and possible UIP patterns (p=0.01) 
identified by Ryerson et al4. Furthermore in both studies, relationships between CT 
pattern and outcome were weak compared to CT fibrosis extent. Though the relative 
proportions of patients in each of the three CT pattern groups (definite, possible and 
inconsistent with UIP) varied between studies, taken together, these findings 
suggest that in patients with uILD, utilization of the IPF-UIP CT diagnostic criteria 
may not be useful in indicating patient outcome. 
 
Change in fibrosis extent scored visually and by CALIPER were equivalent at 
predicting outcome on univariate analysis, but after adjusting for baseline disease 
severity, change in CALIPER fibrosis extent was shown to be a stronger measure of 
outcome than any baseline variable. The cardinal description of uILD by Ryerson et 
al4 identified baseline CT fibrosis as being independently associated with outcome. 
The very nature of uILD presupposes a heterogeneous population in which patients 
with inflammatory etiologies are grouped with established fibrotic conditions. 
Consequently, with variations in disease trajectories across the population, baseline 
disease severity measures may be proportionally less important than robust 
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measures of longitudinal change such as worsening lung fibrosis or relative FVC 
change that reflect disease behavior. 
 
The uILD patient subgroup with longitudinal FVC measurements showed limited 
functional decline (2.5% predicted per year) in contrast to IPF populations in which 
an annual decline of 10% predicted FVC is common in patients not receiving 
therapy31. When FVC declines are marginal, the measurement variation associated 
with FVC32 can reduce its strength as an outcome measure. Yet we have 
demonstrated, albeit in what is essentially pilot data, that in patients with marginal 
declines (<10% predicted relative FVC decline), CALIPER measures of change in 
fibrosis extent strongly and independently predicted outcome after adjustment for 
baseline disease severity. Our findings suggest that quantitative CT analysis has the 
potential to be part of a composite staging system to identify true decline when FVC 
change is marginal. 
 
The interobserver variation associated with visual CT scoring was accentuated when 
variation in scores across two time points were summed to identify disease change. 
A similar effect may be seen with longitudinal DLco assessment where measurement 
inaccuracy would be compounded when DLco is evaluated at two time points. In our 
study, all DLco measurements were performed in a single rigorously calibrated 
laboratory, and yet DLco change had limited associations with outcome.  
 
A limitation of our study is that only a subset of patients had follow up imaging in 
our study, however the similarities in baseline functional indices between patients 
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with and without follow up imaging, suggests that an unintentional selection bias 
towards patients with less severe disease did not explain the prognostic strength of 
CALIPER fibrosis extent change. Our findings suggest that larger studies using 
CALIPER are warranted to characterize the robustness of change in quantitative CT 
markers as measures of disease progression and outcome.  
 
In conclusion, our study of unclassifiable-interstitial lung disease has identified that 
the CPI and visual increased traction bronchiectasis severity and pulmonary artery 
diameter are the strongest independent predictors of outcome at baseline. 
However, in a subset of patients with longitudinal data and similar baseline 
measures, change in fibrosis extent measured by CALIPER was independent of, and 
more powerful than baseline measures of disease severity in patients with uILD. 
Importantly, when FVC decline was marginal, CALIPER fibrosis extent change was 
able to independently predict patient outcome. 
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Variable (n = 95 unless stated) 
Units are percentage unless stated 
 Value 
 
Median Age (years)     65 
Male/female   45/50 
Survival (alive/dead)   55/50 
Never smokers/ex/current smokers   54/36/5 
FEV1 % predicted (n=90)  72.0 ± 23.7 
FVC % predicted (n=90)  72.1 ± 23.8 
DLco % predicted (n=90)  41.3 ± 14.4 
Kco % predicted (n=90)  71.6 ± 18.4 
TLC% predicted (n=87)  69.2 ± 17.2 
CPI (n=87)  52.0 ± 13.3 
Echocardiography RVSP (mmHg) (n=53)  39.7 ± 16.6 
CALIPER ILD extent   26.5 ± 23.8 
CALIPER Fibrosis extent  6.7 ± 6.3 
  CALIPER Ground glass opacity   19.9 ± 20.0 
  CALIPER Reticular pattern   6.2 ± 6.0 
  CALIPER Honeycombing   0.4 ± 1.0 
CALIPER Grade 1+2 decreased attenuation  0.4 ± 1.0 
CALIPER Pulmonary vessel volume   4.8 ± 2.2 
CALIPER Normal lung  68.2 ± 25.6 
Visual ILD extent  44.9 ± 23.1 
Visual fibrosis extent  21.4 ± 15.9 
  Visual Ground glass opacity   22.1 ± 20.8 
  Visual Reticular pattern   17.7 ± 12.6 
  Visual Honeycombing   3.8 ± 7.9 
Visual Emphysema   3.3 ± 7.7 
Visual TxBx severity (max score 18)  4.6 ± 3.1 
Main pulmonary artery diameter (mm)  30.5 ± 5.9 
Ascending aorta diameter (mm)  33.9 ± 3.9 
 
Table 1. Patient age, gender and mean and standard deviations of pulmonary function 
indices, CALIPER and visually scored CT parameters and echocardiography data. Data 
represent mean values with standard deviations. CT = computed tomography, FEV1 = 
forced expiratory volume in one second, FVC = forced vital capacity, DLCO = diffusing 
capacity for carbon monoxide, Kco = carbon monoxide transfer coefficient, TLC = total 
lung capacity, CPI = composite physiological index, ILD = interstitial lung disease, RVSP = 
right ventricular systolic pressure TxBx = traction bronchiectasis.  
  
 22 
 Number of 
patients 
Hazard 
ratio 
P Value 95.0% Confidence Interval 
Lower Upper 
CALIPER score      
  Total ILD extent 95 1.02 0.002 1.01 1.03 
  Total fibrosis extent 95 1.06 0.001 1.02 1.10 
  Ground glass opacity 95 1.02 0.007 1.01 1.03 
  Reticular pattern 95 1.06 0.003 1.02 1.09 
  Honeycombing 95 1.27 0.006 1.07 1.52 
  Grade 2+3 DA  95 1.15 0.29 0.89 1.48 
  Normal lung  95 0.98 0.001 0.98 0.99 
  PVV 95 1.21 0.0003 1.09 1.35 
VISUAL score      
  ILD extent 95 1.02 0.005 1.01 1.03 
  Fibrosis extent 95 1.03 0.0002 1.02 1.05 
  Ground glass opacity 95 1.00 0.85 0.99 1.01 
  Reticular pattern 95 1.03 0.01 1.01 1.05 
  Honeycombing 95 1.04 0.0003 1.02 1.07 
  Total emphysema 95 1.01 0.44 0.98 1.05 
  TxBx severity 95 1.27 <0.0001 1.16 1.38 
  Main PA 95 1.11 <0.0001 1.05 1.16 
  PA:Ao ratio 95 1.59 0.003 1.16 2.14 
  Honeycombing presence 95 3.39 0.0001 1.81 6.35 
Definite UIP pattern 95 2.72 0.04 1.07 6.90 
Lung Function Indices      
  FEV1 90 0.97 0.0002 0.96 0.99 
  FVC  90 0.97 <0.0001 0.95 0.98 
  TLC 87 0.95 <0.0001 0.94 0.97 
  DLco 90 0.94 <0.0001 0.91 0.96 
  Kco 90 0.98 0.04 0.96 1.00 
  CPI 87 1.09 <0.0001 1.06 1.12 
ECHOCARDIOGRAPHY      
  RVSP 53 1.02 0.02 1.00 1.04 
 
Table 2. Univariate Cox regression analysis demonstrating mortality according to CALIPER 
indices (top white), visually derived HRCT indices (light grey), pulmonary function tests (dark 
grey) and echocardiography (bottom white). ILD=Interstitial lung disease, DA=decreased 
attenuation, TxBx=traction bronchiectasis, PA=pulmonary artery, Ao=Aorta, PVV= 
pulmonary vessel volume, FEV1=forced expiratory volume in one second, FVC=forced vital 
capacity, TLC=total lung capacity, DLco=diffusing capacity for carbon monoxide, Kco=Carbon 
monoxide transfer coefficient, CPI=composite physiologic index, RVSP=right ventricular 
systolic pressure. Fibrosis extent is sum of reticular pattern and honeycombing. ILD extent 
additionally summed ground glass opacities.  
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Change in variables  
(per year) 
Number of 
patients 
Hazard 
ratio 
P Value 95.0% Confidence Interval 
Lower Upper 
CALIPER score      
  Total ILD change  37 1.02   0.22 0.99 1.04 
  Total fibrosis change 37 1.17   0.0002 1.08 1.27 
  Ground glass opacity change 37 1.00   0.84 0.98 1.03 
  Reticular pattern change 37 1.16   0.001 1.07 1.26 
  Honeycombing change 37 1.42   0.17 0.86 2.34 
  Grade 2+3 DA change 37 1.95   0.09 0.90 4.19 
  Normal lung change 37 0.98   0.15 0.96 1.01 
  PVV change 37 2.07   0.006 1.23 3.50 
VISUAL score      
  ILD extent change 37 1.05   0.02 1.01 1.09 
  Fibrosis extent change 37 1.09 <0.0001 1.04 1.14 
  Ground glass opacity change 37 1.00   0.86 0.97 1.04 
  Reticular pattern change 37 1.07   0.008 1.02 1.12 
  Honeycombing change 37 1.11   0.002 1.04 1.19 
  Total emphysema change 37 0.91   0.32 0.77 1.09 
  TxBx severity change 37 1.31   0.04 1.01 1.69 
  Main PA change 37 1.07   0.30 0.95 1.20 
Lung Function Indices      
  Absolute FVC change 34 0.92   0.003 0.88 0.97 
  Relative FVC change 34 0.93   0.0002 0.90 0.97 
  Absolute DLco change 34 0.92   0.03 0.85 0.99 
  Relative DLco change 34 0.96   0.01 0.92 0.99 
  Absolute CPI change 32 1.13   0.009 1.03 1.24 
 
Table 3. Univariate Cox regression analysis demonstrating mortality according to annualized 
change in CALIPER indices (top white), visually derived HRCT indices (light grey) and 
pulmonary function tests (dark grey). ILD=Interstitial lung disease, DA=decreased 
attenuation, TxBx=traction bronchiectasis, PA=pulmonary artery, PVV=pulmonary vessel 
volume, FVC=forced vital capacity, DLco=diffusing capacity for carbon monoxide, 
CPI=composite physiologic index. Fibrosis extent is sum of reticular pattern and 
honeycombing. ILD extent additionally summed ground glass opacities.  
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Change in variables  
(per year) 
Number of 
patients 
Hazard 
ratio 
P Value 95.0% Confidence Interval 
Lower Upper 
CALIPER score      
  Total ILD change  29 1.02   0.13 1.00 1.04 
  Total fibrosis change 29 1.16   0.001 1.07 1.26 
  Ground glass opacity change 29 1.01   0.37 0.98 1.04 
  Reticular pattern change 29 1.14   0.001 1.06 1.24 
  Honeycombing change 29 1.41   0.16 0.87 2.28 
  Grade 2+3 DA change 29 1.71   0.18 0.77 3.71 
  Normal lung change 29 0.98   0.10 0.96 1.00 
  PVV change 29 2.27   0.005 1.28 4.04 
VISUAL score      
  ILD extent change 29 1.04   0.05 1.01 1.09 
  Fibrosis extent change 29 1.08   0.0005 1.04 1.13 
  Ground glass opacity change 29 0.99   0.67 0.94 1.04 
  Reticular pattern change 29 1.06   0.03 1.01 1.11 
  Honeycombing change 29 1.10   0.009 1.02 1.18 
  Total emphysema change 29 4.10   0.02 1.30 12.93 
  TxBx severity change 29 1.19   0.24 0.89 1.58 
  Main PA change 29 1.02   0.72 0.91 1.15 
Lung Function Indices      
  Absolute FVC change 29 0.93   0.01 0.87 0.98 
  Relative FVC change 29 0.93   0.001 0.89 0.97 
  Absolute DLco change 27 0.91   0.04 0.83 0.99 
  Relative DLco change 27 0.95   0.009 0.91 0.99 
  Absolute CPI change 27 1.13   0.02 1.02 1.25 
 
Table 4. Univariate Cox regression analysis in patients with a relative FVC decline <10% 
predicted. The table demonstrates mortality according to annualized change in CALIPER 
indices (top white), visually derived HRCT indices (light grey) and pulmonary function tests 
(dark grey). ILD=Interstitial lung disease, DA=decreased attenuation, TxBx=traction 
bronchiectasis, PA=pulmonary artery, PVV=pulmonary vessel volume, FVC=forced vital 
capacity, DLco=diffusing capacity for carbon monoxide, CPI=composite physiologic index. 
Fibrosis extent is sum of reticular pattern and honeycombing. ILD extent additionally 
summed ground glass opacities. 
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Figure 1. CT imaging for two patients who were found to be inconsistent for a UIP 
pattern on CT. Patient A (Axial image), a 77-year-old never smoker demonstrated 
peribronchovascular and perilobular consolidation in keeping with an organizing 
pneumonia pattern, but did not fulfill criteria for undifferentiated connective tissue 
disease. Patient B (Coronal image) a 79-year-old never smoker, demonstrated an 
upper lobe predominant pattern of fibrosis but had no associated CT or clinical 
features of hypersensitivity pneumonitis and was given a differential diagnosis of 
idiopathic pulmonary fibrosis/chronic hypersensitivity pneumonitis. 
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